Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Editas Medicine, Inc. Director's Dealing 2021

Dec 23, 2021

33260_dirs_2021-12-23_1198f31c-7461-4b22-9117-23e14ca754c8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2021-12-22

Reporting Person: Eaton Bruce (EVP, Chief Business Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-12-22 Common Stock A 3472 Acquired 31498 Direct

Footnotes

F1: Reflects the acquisition, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2021. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on June 2, 2022, subject to continued service.